Inappropriately chelated iron in the cerebrospinal fluid of amyotrophic lateral sclerosis patients.
Aleksandar IgnjatovićZorica StevićDragana LavrnićAleksandra Nikolić-KokićDuško BlagojevićMihajlo SpasićIvan SpasojevićPublished in: Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases (2012)
ALS is characterized by oxidative damage in the brain and cerebrospinal fluid, which is exerted by pro-oxidative activity of iron. Such activity of iron can be drastically increased in the presence of inappropriate iron ligands that catalyze redox cycling of iron, thereby promoting hydroxyl radical generation. The aim of our study was to determine the relative level of inappropriate iron ligands in the cerebrospinal fluid of ALS patients. To determine the levels of inappropriate iron ligands and redox activity of iron in cerebrospinal fluid (10 samples from ALS patients and 10 controls), we applied electron paramagnetic resonance spectroscopy. We have shown that cerebrospinal fluid of ALS patients comprises two-fold increased level of inappropriate iron ligands, proportionally increasing iron redox activity and hydroxyl radical production compared to controls. In conclusion, our results strongly support the pro-oxidative/detrimental role of inappropriately chelated iron in ALS pathophysiology. The identification of biomolecules that form such iron complexes and their therapeutic targeting may represent the future of ALS treatment.
Keyphrases
- cerebrospinal fluid
- amyotrophic lateral sclerosis
- end stage renal disease
- iron deficiency
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- multiple sclerosis
- patient reported outcomes
- drug delivery
- high intensity
- current status
- smoking cessation
- cancer therapy
- blood brain barrier
- single molecule
- combination therapy
- cerebral ischemia
- anti inflammatory
- quantum dots